Aadi Bioscience, Inc. is a biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi’s primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations.
FYARRO™ (sirolimus protein-bound particles for injectable suspension) (albumin-bound), is the first and only FDA approved therapy for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
Additional Info
Will your company display a new product or promote a new indication/enhanced feature(s) for an existing product in your booth?
Yes